HFD administration leads to pulmonary fibrosis by causing insulin resistance, a chronic inflammatory response, pro-oxidative/antioxidative imbalance, and increased levels of profibrogenic factors, including TGF-β, IL-17, NE, and MMP-9. The gene discussed is TGFB1; the disease is pulmonary fibrosis.